Abstract 800: Spatial accessibility of gynecologic oncologists and time to surgery in a diverse cohort of women with ovarian cancer in Northern California. Read more about Abstract 800: Spatial accessibility of gynecologic oncologists and time to surgery in a diverse cohort of women with ovarian cancer in Northern California.
Abstract 768: Awareness and use of genetic testing among cancer survivors in the United States: A HINTS-SEER study. Read more about Abstract 768: Awareness and use of genetic testing among cancer survivors in the United States: A HINTS-SEER study.
Abstract 4827: Financial toxicity among cancer survivors during the COVID-19 pandemic. Read more about Abstract 4827: Financial toxicity among cancer survivors during the COVID-19 pandemic.
Abstract 2227: Physical activity at breast cancer diagnosis and incident cardiovascular disease in the Pathways Study. Read more about Abstract 2227: Physical activity at breast cancer diagnosis and incident cardiovascular disease in the Pathways Study.
Abstract 4653: Unraveling the vulnerabilities of targeted therapy-tolerant persister cells in NSCLC. Read more about Abstract 4653: Unraveling the vulnerabilities of targeted therapy-tolerant persister cells in NSCLC.
Abstract 3460: Predicting cessation of immune checkpoint inhibitor therapy due to severe adverse events with an integrated autoimmune disease polygenic risk score. Read more about Abstract 3460: Predicting cessation of immune checkpoint inhibitor therapy due to severe adverse events with an integrated autoimmune disease polygenic risk score.
Abstract A046: nSMase2-generated ceramide promotes PDA aggression through exosome reprogramming of the stroma. Read more about Abstract A046: nSMase2-generated ceramide promotes PDA aggression through exosome reprogramming of the stroma.
To Tip or Not to Tip: A New Combination for Precision Medicine in Head and Neck Cancer. Read more about To Tip or Not to Tip: A New Combination for Precision Medicine in Head and Neck Cancer.
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer. Read more about The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.
PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING-Type I Interferon Signaling in Glioblastoma. Read more about PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING-Type I Interferon Signaling in Glioblastoma.
